Hughes DA - Search Results

1

Hughes DA. Hughes DA. Br J Clin Pharmacol. 2012 Jun;73(6):968-72. doi: 10.1111/j.1365-2125.2012.04247.x. Br J Clin Pharmacol. 2012. PMID: 22360714 Free PMC article.

2

Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.

Hill-McManus D, Marshall S, Soto E, Hughes DA. Hill-McManus D, et al. Among authors: hughes da. Clin Pharmacol Ther. 2019 Sep;106(3):652-660. doi: 10.1002/cpt.1454. Epub 2019 May 31. Clin Pharmacol Ther. 2019. PMID: 30993686

3

Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?

Hughes DA. Hughes DA. Clin Pharmacol Ther. 2018 May;103(5):749-751. doi: 10.1002/cpt.1030. Epub 2018 Feb 13. Clin Pharmacol Ther. 2018. PMID: 29435984

4

Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.

Hill-McManus D, Marshall S, Liu J, Willke RJ, Hughes DA. Hill-McManus D, et al. Among authors: hughes da. Clin Pharmacol Ther. 2021 Jul;110(1):49-63. doi: 10.1002/cpt.2051. Epub 2020 Oct 26. Clin Pharmacol Ther. 2021. PMID: 32936931 Review.

5

From NCE to NICE: the role of pharmacoeconomics.

Hughes DA. Hughes DA. Br J Clin Pharmacol. 2010 Sep;70(3):317-9. doi: 10.1111/j.1365-2125.2010.03708.x. Br J Clin Pharmacol. 2010. PMID: 20716229 Free PMC article. No abstract available.

6

Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.

Linley WG, Hughes DA. Linley WG, et al. Among authors: hughes da. Pharmacoeconomics. 2013 Apr;31(4):345-55. doi: 10.1007/s40273-013-0030-0. Pharmacoeconomics. 2013. PMID: 23516033

7

Affordable orphan drugs: a role for not-for-profit organizations.

Davies EH, Fulton E, Brook D, Hughes DA. Davies EH, et al. Among authors: hughes da. Br J Clin Pharmacol. 2017 Jul;83(7):1595-1601. doi: 10.1111/bcp.13240. Epub 2017 Feb 8. Br J Clin Pharmacol. 2017. PMID: 28109021 Free PMC article. Review.

8

Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program.

Ridyard CH, Hughes DA. Ridyard CH, et al. Among authors: hughes da. Value Health. 2010 Dec;13(8):867-72. doi: 10.1111/j.1524-4733.2010.00788.x. Epub 2010 Oct 12. Value Health. 2010. PMID: 20946187 Free article. Review.

9

Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.

Pink J, Lane S, Hughes DA. Pink J, et al. Among authors: hughes da. Pharmacoeconomics. 2012 May;30(5):413-29. doi: 10.2165/11591540-000000000-00000. Pharmacoeconomics. 2012. PMID: 22428718

10

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

Pink J, Lane S, Pirmohamed M, Hughes DA. Pink J, et al. Among authors: hughes da. BMJ. 2011 Oct 31;343:d6333. doi: 10.1136/bmj.d6333. BMJ. 2011. PMID: 22042753 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

523 results

Search Page